MarketPulse

warrants

16 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Univest Securities, Llc

Univest Closes $16M Offering for Wire Harness Maker Linkers Industries

Univest Securities closed a $16 million public offering for wire harness maker Linkers Industries, raising capital for acquisitions and operations.
LNKSwarrantspublic offering
BenzingaBenzinga··Globe Newswire

EV Maker LOBO Prices $2M Public Offering to Fund Development

LOBO Technologies prices $2M public offering of 3.9M units at $0.51 each, with proceeds for EV development and working capital.
LOBOwarrantspublic offering
BenzingaBenzinga··Not Specified

Outlook Therapeutics Launches Capital Raise Through Public Stock Offering

Outlook Therapeutics launches best-efforts public offering of stock and warrants with H.C. Wainwright as placement agent, subject to market conditions.
OTLKwarrantspublic offering
BenzingaBenzinga··Globe Newswire

Reviva Pharmaceuticals Closes $10M Offering to Fund Schizophrenia Drug Trial

Reviva Pharmaceuticals closed a $10M public offering at $1.50/share to fund its RECOVER-2 Phase 3 schizophrenia trial, maintaining $23M cash through Q1 2027.
RVPHwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nyxoah SA Reports 10.14% Stake Crossing via Transparency Notification

Nyxoah SA disclosed that Robert Taub and Robelga SRL exceeded 3% voting threshold in December 2025, holding 10.14% combined stake.
NYXHvoting rightswarrants
BenzingaBenzinga··Globe Newswire

Reviva Pharma Raises $10M via Public Offering to Fund Schizophrenia Drug Trial

Reviva Pharma raises $10M via share offering priced at $1.50 per share to fund Phase 3 schizophrenia drug trial through March 2026 closing.
RVPHwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Reviva Pharma Raises $10M via Public Offering to Fund Schizophrenia Drug Trial

Reviva Pharmaceuticals prices $10M offering at $1.50/share to fund brilaroxazine Phase 3 schizophrenia trial and operations.
RVPHwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Quantum BioPharma Adjusts Debenture Terms Amid Share Price Decline

Quantum BioPharma revises debenture offering terms following share price decline, lowering conversion price to $3.00 and increasing warrant allocation.
QNTMwarrantsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Bioxcel Therapeutics, Inc.

BioXcel Therapeutics Raises $8M via Direct Offering Amid Market Challenges

BioXcel Therapeutics raises $8M via direct offering of 4.5M shares at $1.739/share, with warrant modifications agreed, closing expected March 2026.
BTAIartificial intelligencewarrants
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Calidi Biotherapeutics Raises $6M in Public Offering, Exercises Full Warrant Overallotment

Calidi Biotherapeutics closed a $6 million underwritten public offering, issuing 12.1 million shares and Series J, K, L warrants with $0.50 exercise prices.
CLDIwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Closes $1.8M Rights Offering to Fund Pancreatic Cancer Drug

AIM ImmunoTech closes $1.8M rights offering to advance Ampligen immunotherapy development for late-stage pancreatic cancer treatment.
AIMclinical trialswarrants
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Calidi Biotherapeutics Launches Public Offering to Bolster Growth

Calidi Biotherapeutics launches underwritten public offering of common stock and warrants, with Ladenburg Thalmann managing the raise for working capital and corporate purposes.
CLDIwarrantspublic offering
BenzingaBenzinga··Globe Newswire

AIM ImmunoTech Raises $1.8M Through Rights Offering as Biotech Seeks Capital

AIM ImmunoTech raises $1.8M through rights offering expiring March 3, 2026, providing working capital for ongoing immunotherapy operations.
AIMwarrantscapital raise
BenzingaBenzinga··Prnewswire

Juggernaut Exploration Secures C$10M Through Flow-Through Private Placement

Juggernaut Exploration raises C$10M through flow-through private placement to fund exploration of its Big One Gold Project in British Columbia's Golden Triangle.
SFSFBSFpBSFpCSFpDbought dealprivate placement
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Bimergen Energy to List on NYSE American After $13.6M Offering

Bimergen Energy prices $13.6M IPO at $4 per share, listing on NYSE American February 20. Proceeds fund battery energy storage projects.
BESSwarrantspublic offering
BenzingaBenzinga··Globe Newswire

Liminatus Pharma Prices $4M Share Offering to Fund Immuno-Oncology Pipeline

Liminatus Pharma prices $4M share offering to fund immuno-oncology pipeline development, specifically advancing CD47-blockade therapeutic programs.
LIMNLIMNWwarrantspublic offering